Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;3(3):e00130.
doi: 10.1002/prp2.130. Epub 2015 Jun 1.

Pharmacokinetic study of metopimazine by oral route in children

Eric Mallet  1 , Frederic Bounoure  2 , Mohamed Skiba  2 , Elodie Saussereau  3 , Jean-Pierre Goullé  3 , Mireille Castanet  1
Affiliations

Pharmacokinetic study of metopimazine by oral route in children

Eric Mallet et al. Pharmacol Res Perspect. 2015 Jun.

Abstract

Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator due to its good tolerance, however, its pharmacokinetics has never previously been studied in children. MPZ was administered by oral route to 8 children with a single dose of 0.33 mg/kg during an endocrine exploration using stimuli well known for its adverse emetic effects. We used biological remnants from sera following an hGH test in order to obtain the MPZ pharmacokinetics. Plasmatic concentrations of MPZ and the active acid metabolite AMPZ, were quantified by HPLC-MS/MS during a 270 min test period. MPZ is quickly absorbed with a median C max of 17.2 ng/mL at one hour and its half-life is 2.18 h. The plasmatic concentrations of AMPZ were higher than MPZ with a median C max of 76.3 ng/mL, a T max to 150 min and its concentration was approximately maintained at 50 ng/mL from 1 to 4 h. The plasmatic concentrations in children are similar to those observed in adults. No adverse effects, nausea or vomiting occurred during the trial. Therefore, these results confirm the MPZ dosage that should be used in children under 15 kg administered as 0.33 mg/kg up to 3 times a day.

Keywords: Antiemetic drug; children; metopimazine; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasmatic concentration of metopimazine in eight children.
Figure 2
Figure 2
Plasmatic concentration of metopimazine in eight children.
Figure 3
Figure 3
Mean plasmatic concentration of metopimazine (MPZ) and acid of MPZ in children (n = 8).
See this image and copyright information in PMC

References

    1. ANSM. 2011. Médicaments à base de dompéridone et sécurité d’emploi cardiovasculaire - Lettre aux professionnels de santé du 06/12/2011.
    1. ANSM. 2012. Contre-indication des spécialités à base de métoclopramide (Primpéran® et génériques) chez l’enfant et l’adolescent et renforcement des informations sur les risques neurologiques et cardiovasculaires - Lettre aux professionnels de santé du 08/02/2012.
    1. Colle M, Battin J, Coquelin JP, Rochiccioli P. Betaxolol and propranolol in glucagon stimulation of growth hormone. Arch Dis Child. 1984;59:670–672. - PMC - PubMed
    1. Dillman JR, Smith EA, Khalatbari S, Strouse PJ. I.v. glucagon use in Pediatric MR enterography: effect on image quality, length of examination, and patient tolerance. AJR Am J Roentgenol. 2013;201:185–189. - PubMed
    1. Bounoure F, Lahiani SkibaM, Besnard M, Arnaud P, Mallet E, Skiba M. Effect of iontophoresis and penetration enhancers on transdermal absorption of metopimazine. J Dermatol Sci. 2008;52:170–177. - PubMed